BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc. (Nasdaq: BBOT) is a blank-check company targeting the oncology and healthcare therapeutics sector. The company filed its Form 10-Q with the SEC on August 1, 2025, bearing accession number 0001213900-25-070659, reflecting its ongoing reporting obligations as a publicly traded special purpose acquisition company. BBOT remains active in its search for a qualifying business combination within the life sciences and biopharmaceutical space, an area that has drawn significant SPAC attention in recent years. Investors and analysts tracking BBOT's deal pipeline, filing history, and comparable transactions can access full data and analytics on SpacDesk — sign up today at spacdesk.com.